167 Matching Annotations
  1. Aug 2022
    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. ReconfigBehSci. (2021, December 13). RT @DrEricDing: 11) Omicron is doubling every 1.6 days in UK 🇬🇧 according to @DrWilliamKu’s figure. That’s way faster growth than in South… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1470451594378502154

  2. Apr 2022
    1. Carlos del Rio. (2021, April 7). U.K. variant now dominant form of COVID in US ⁦@CDCDirector⁩ As predicted B.1.1.7 is now the predominant SARS-CoV-2 strain in the US. Let’s remember it is much more transmissible and likely also more severe. Vaccines do cover it. ⁦@ajc⁩ https://t.co/Wc4oaYkxqR [Tweet]. @CarlosdelRio7. https://twitter.com/CarlosdelRio7/status/1379816377356333057

    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Prof. Christina Pagel. (2021, May 3). THREAD: Update on B.1.617 (‘India’) variant in England using latest data from the Sanger institute. This data excludes sequenced cases from travellers & surge testing so ‘should be an approximately random sample of positive tests in the community’ TLDR: warning signs! 1/10 https://t.co/0UzhM8GNIA [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1389273187586875396

    1. (1) ReconfigBehSci on Twitter: ‘RT @ScottGottliebMD: The U.K. is experiencing a growing surge of COVID infections with a new variant that appears more pathogenic, and that…’ / Twitter. (n.d.). Retrieved 21 June 2021, from https://twitter.com/SciBeh/status/1402048528189300737

    1. Marc Lipsitch. (2021, July 20). At the risk of boiling down too much and certainly losing some detail, one way to summarize this wonderful thread is that when we think about vaccine effectiveness, we should think of 4 key variables: 1 which vaccine, 2 age of the person, 3 how long after vax, 4 vs what outcome. [Tweet]. @mlipsitch. https://twitter.com/mlipsitch/status/1417595538632060931

  3. Feb 2022
  4. Jan 2022
    1. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw, D., Elliott, J., Whitaker, M., Walters, C., Atchison, C., Diggle, P., Page, A., Trotter, A., Ashby, D., Barclay, W., Taylor, G., Ward, H., Darzi, A., … Donnelly, C. (2022). Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 [Working Paper]. http://spiral.imperial.ac.uk/handle/10044/1/93887

    1. Keeling, M. J., Brooks-Pollock, E., Challen, R. J., Danon, L., Dyson, L., Gog, J. R., Guzman-Rincon, L., Hill, E. M., Pellis, L. M., Read, J. M., & Tildesley, M. (2021). Short-term Projections based on Early Omicron Variant Dynamics in England. (p. 2021.12.30.21268307). https://doi.org/10.1101/2021.12.30.21268307

  5. Dec 2021
    1. Colin Davis. (2021, December 20). Update for 20th Dec. The trend line still reflects 1.8 day doubling (it’s 1.7 days if we look at just the last week). Today’s number is down, but I wouldn’t read too much into that at this point. Https://t.co/kOCjxhRbop [Tweet]. @ProfColinDavis. https://twitter.com/ProfColinDavis/status/1472969632705392640

    1. Dr Duncan Robertson. (2021, December 15). Cases on the dashboard exclude reinfections.And there are a lot of reinfections as far as Omicron is concerned h/t @AlistairHaimes and @Peston And this is only cases reported today—Not from infections today With a 2-day doubling time for Omicron, this isn’t great https://t.co/fU2RLhshtn [Tweet]. @Dr_D_Robertson. https://twitter.com/Dr_D_Robertson/status/1471156538681315336

    1. Eric Feigl-Ding. (2021, December 2). A rise in possible #Omicron in England—Tripling (0.1 to 0.3) of S-Gene dropout PCR signal, which is a proxy for Omicron (before 🧬 sequencing confirms). @_nickdavies estimates this represents around ~60 cases in 🏴󠁧󠁢󠁥󠁮󠁧󠁿. Still early—But it displacing #DeltaVariant is not good sign. 🧵 https://t.co/4aIiqiVsqH [Tweet]. @DrEricDing. https://twitter.com/DrEricDing/status/1466234026843205637

  6. Nov 2021
    1. Prof. Christina Pagel. (2021, November 24). Meanwhile AY.4.2 (Delta grandchild) continues its very slow path to English dominance. Makes life a bit harder by being a bit more transmissible but luckily doesn’t seem any worse than Delta in any other respect. Https://t.co/kB0V0Z66GT [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1463508172941967365

    1. Jeffrey Barrett. (2021, October 19). Proportion of AY.4.2 (now on http://covid19.sanger.ac.uk) has been steadily increasing in England, which is a pattern that is quite different from other AY lineages. Several of them rose when there was still Alpha to displace, but none has had a consistent advantage vs other Delta. Https://t.co/mD5gQzKxgV [Tweet]. @jcbarret. https://twitter.com/jcbarret/status/1450408485829718039

    1. Prof. Christina Pagel. (2021, November 3). Good @NatGeo article by @Ecquis on the growing AY.4.2 variant in the UK with lots of great experts explaining it. And a little bit of me too! At its current growth rate, it will probably become dominant in UK by the end of the year. Https://t.co/X9O9kbew2L [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1455899379475361795

    1. Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook, D., Rourke, E., Studley, R., Peto, T. E. A., Diamond, I., & Walker, A. S. (2021). Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01548-7